Disclaimer This presentation (Presentation) is for informational purposes only. The information contained herein does not
purport to be all-inclusive and neither Better Therapeutics, Inc. (BetterTX or the Company) nor any of its respective affiliates nor any of its or their control persons, officers,
directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and
financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision. The reader shall not
rely upon any statement, representation or warranty made by any other person, firm or corporation in making its investment or decision to invest in the Company. Neither the Company nor any of its respective affiliates nor any of its or their control
persons, officers, directors, employees or representatives, shall be liable to the reader for any information set forth herein or any action taken or not taken by any reader, including any investment in shares of the Company. Certain information
contained in this Presentation relates to or is based on studies, publications, surveys and the Companys own internal estimates and research. In addition, all of the market data included in this Presentation involves a number of assumptions
and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting
and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization. Forward-Looking Statements. Certain statements in this Presentation may be considered forward-looking statements,
within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as plan, believe,
expect, anticipate, intend, outlook, estimate, forecast, project, continue, could, may, might, possible,
potential, predict, should, would and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this
press release include, but are not limited to, statements regarding the timing and results of the ongoing trial of BT-001 in patients with type 2 diabetes, the Companys plans regarding FDA submissions
expectations related to the potential benefits of BT-001 and CBT and their potential treatment applications, the Companys plans regarding the research and advancement of its product candidates for
additional treatments, expectations related to the interest of healthcare providers and payers in PDTs and legislative developments affecting PDTs and the outcome of such developments, among others. These forward-looking statements are based on the
current expectations of the management of the Company and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future
developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or
implied by these forward-looking statements including: risks related to the Companys business, such as the willingness of the FDA to authorize PDTs for commercial distribution and insurance companies to reimburse their use, market acceptance
of PDTs, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates and other risks and uncertainties included under the header Risk Factors in
the definitive proxy statement/prospectus filed by us on October 12, 2021. 2